|
⚲
|
| Keyboard |
| Amy Schulman | |
|---|---|
| Firm | |
| Address | 131 Varick Street 11th Floor New York, NY 10013 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| MeridianMade Inc | 021-592098 | Director | 20.3 M of 20.3 M |
||
| Sequelae Inc | 021-564316 | Director | 0.2 M of 1.5 M |
||
| Quralis Corp | 021-556816 | Director | 20.0 M of 24.9 M |
||
| Byheart Inc | 021-542353 | Director | 72.2 M of 173.1 M |
||
| Noetik Inc | 021-521402 | Director | 40.0 M of 40.0 M |
||
| Sequelae Inc | 021-512641 | Director | 20.0 M of 20.0 M |
||
| Sequelae Inc | 021-510405 | Director | 60.0 M of 60.0 M |
||
| Byheart Inc | 021-509961 | Director | 95.5 M of 95.5 M |
||
| Lyndra Therapeutics Inc | 021-501189 | Director | 122.7 M of 206.1 M |
||
| Lyndra Therapeutics Inc | 021-483559 | Director | 20.4 M of 179.3 M |
||
| Quralis Corp | 021-475621 | Director | 60.0 M of 88.0 M |
||
| Volastra Therapeutics Inc | 021-475679 | Director | 60.2 M of 60.2 M |
||
| Byheart Inc | 021-470671 | Director | 29.6 M of 60.0 M |
||
| Cardurion Pharmaceuticals Inc | 021-469288 | Director | 17.5 M of 17.5 M |
||
| Amagma Inc | 021-468628 | Director | 10.0 M of 10.0 M |
||
| Quralis Corp | 021-457747 | Director | 5.0 M of 10.0 M |
||
| Amagma Inc | 021-447704 | Director | 2.3 M of 2.3 M |
||
| Thirty Madison Inc | 021-439554 | Director | 112.0 M of 112.0 M |
||
| Fractyl Health Inc | 021-430685 | Director | 20.1 M of 20.1 M |
||
| Glympse Bio Inc | 021-425703 | Director | 18.0 M of 18.0 M |
||
| Cardurion Pharmaceuticals Inc | 021-419648 | Director | 128.1 M of 128.1 M |
||
| Byheart Inc | 021-407954 | Director | 62.2 M of 90.0 M |
||
| Lyndra Therapeutics Inc | 021-403985 | Director | 60.5 M of 65.0 M |
||
| Fractyl Health Inc | 021-403725 | Director | 100.0 M of 100.0 M |
||
| Thirty Madison Inc | 021-401543 | Director | 141.0 M of 141.0 M |
||
| Cyclerion Therapeutics Inc | 021-372991 | Director | 24.2 M of 24.2 M |
||
| Glympse Bio Inc | 021-368862 | Director | 46.7 M of 46.7 M |
||
| SQZ Biotechnologies Co | 021-368023 | Director | 66.3 M of 70.2 M |
||
| Quralis Corp | 021-367164 | Director | 33.2 M of 60.0 M |
||
| Byheart Inc | 021-364097 | Director | 96.9 M of 102.1 M |
||
| Fractyl Laboratories Inc | 021-363219 | Director | 44.8 M of 44.8 M |
||
| Amagma Inc | 021-361645 | Director | 16.4 M of 16.4 M |
||
| Candesant Biomedical Inc | 021-360786 | Director | 9.1 M of 9.1 M |
||
| SQZ Biotechnologies Co | 021-354117 | Director | 71.3 M | ||
| Cardurion Pharmaceuticals Inc | 021-353793 | Director | 10.0 M of 10.0 M |
||
| Cyclerion Therapeutics Inc | 021-337559 | Director | 175.0 M of 175.0 M |
||
| Lyndra Inc | 021-331551 | Executive Officer | 55.2 M of 60.9 M |
||
| Glympse Bio Inc | 021-318570 | Director | 26.1 M of 30.1 M |
||
| Quentis Therapeutics Inc | 021-306751 | Director | 19.7 M of 47.9 M |
||
| Arsanis Inc | 021-300012 | Director | 20.0 M of 20.0 M |
||
| Suono Bio Inc | 021-289354 | Director | 1.3 M of 2.0 M |
||
| Arsanis Inc | 021-286233 | Director | 45.5 M of 50.5 M |
||
| SQZ Biotechnologies Co | 021-271785 | Executive Officer | 24.1 M of 24.1 M |
||
| Lyndra Inc | 021-266863 | Executive Officer | 23.1 M of 23.1 M |
||
| Arsanis Inc | 021-262117 | Director | 15.0 M of 15.0 M |
||
| Arsanis Inc | 021-254201 | Director | 4.0 M of 4.0 M |
||
| SQZ Biotechnologies Co | 021-242788 | Director | 5.1 M of 5.1 M |
||
| Arsanis Inc | 021-201235 | Director | 20.0 M of 20.0 M |
||
| Polaris Growth Management LLC | |||||
| Polaris Partners Xi LP | 021-561568 | Executive Officer | of 500.0 M |
132.6 M | |
| Polaris Partners X LP | 021-433169 | Executive Officer | 354.6 M of 355.0 M |
378.6 M | |
| Polaris Healthcare Technology Opportunities Fund LP | 021-369623 | Executive Officer | of 100.0 M |
70.3 M | |
| Polaris Partners IX LP | 021-342127 | Executive Officer | of 400.0 M |
395.4 M | |
| Related People Network |
|---|
| Network #459 at Arsanis Inc — files alongside 10 co-filers |